Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Diagnosing rare genetic conditions within minutes

Moon is a new software package that, within minutes, diagnoses patients who suffer from rare diseases. All the software requires are the patient’s…

POPULAR TAGS

UgenTec receives €50.000 grant by European Union

Written by DS on in the category news with the tags , , .


Under guidance of MINT, the Belgian PCR automation software company is one out of two Belgian companies to be granted and part of 36 grantees amongst 507 requests.

UgenTec, the Belgian PCR automation software company is approved for the SME Instrument Phase 1 by the European Horizon 2020 fund. The Instrument Phase 1 grant is worth €50.000 and will be used for a feasibility study of new PCR markets outside of clinical diagnostics.

UgenTec focuses on the clinical diagnostic market and their platform already supports tests for sexually transmitted infections (STIs), respiratory diseases, gastrointestinal diseases, oncology and more. Its artificially intelligent software allows laboratories to automate the manual interpretation of raw results generated by PCR tests, resulting in faster & more standardized results.

“PCR is a widely adopted diagnostic technique” says Tom Martens, managing director at UgenTec “FastFinder, our solution for automated PCR interpretation, is being used in clinical diagnostic environments in multiple countries. Thanks to MINT Europe, these European funds can now be used to thoroughly investigate the potential in other diagnostic environments such as seed, food & animal health”.

"We immediately recognized the innovative nature of UgenTec's core technology" says Sofie Meerschaut, Senior Consultant at MINT, "thanks to close collaboration with UgenTec, we understand their current business success and the potential for other markets. The combination of this strategic understanding, both technically and businesswise, and our deep EC grant expertise, allows us to ensure access to EC grants for UgenTec."

The SME Instrument Phase 1 is one of two available grants and is widely used to perform a technical & commercial feasibility study before applying for the SME Instrument Phase 2. When the generated business plan is approved as sound & strategic the company receives access to the SME Instrument Phase 2. This additional grant is used to execute the business plan and unlocks €500.000 to €2.500.000 in funds.

Read more about: , , .

RELATED ARTICLES
Diagnosing rare genetic conditions within minutes

Moon is a new software package that, within minutes, diagnoses patients who suffer from rare diseases. All the software requires are the patient’s…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

NLO Flanders.bio V-Bio Ventures KU Leuven Turnstone UGent Itera Life Science Janssen Biowin GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.